



Material Safety Data Sheet

12601 Twinbrook Parkway
Rockville, MD 20852 USA

Telephone calls: (301) 881-0666
8:00am - 5:00pm EST Mon. - Fri.

Responsible Party: Reference Standards Technical Services

ATTENTION !

USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.

HEXOBARBITAL

Catalog Number: 1307003

Package Size: 500 mg

Revision Date:

May 26, 2004

EMERGENCY OVERVIEW - Reproductive Hazard.

SECTION 1 - IDENTIFICATION

Common Name: Hexobarbital

Formula: C₁₂H₁₆N₂O₃

Synonym: Hexobarbitone

Chemical Name: 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl

CAS Number: 56-29-1

RTECS Number: CQ2625000

Chemical Family: 5,5-Disubstituted pyrimidinetrione

Therapeutic Category: Sedative-hypnotic (barbiturate)

SECTION 2 - INGREDIENT INFORMATION

Principle Components

Percent

Exposure Limits

Hexobarbital

Pure Material

n/f

SECTION 3 - HEALTH HAZARD INFORMATION

Usual Adult Dose: The usual oral adult dose of hexobarbital is 250 to 500 mg.

Adverse Effects: Adverse effects of barbiturates may include confusion, mental depression, unusual excitement, clumsiness or unsteadiness, dizziness or lightheadedness, drowsiness, "hangover" effects, anxiety or nervousness, constipation, feeling faint, headache, irritability, nausea or vomiting, and nightmares or trouble sleeping. Possible allergic reaction to material if inhaled, ingested or in contact with skin.

Overdose Effects: In acute barbiturate overdose, overdose effects may not occur until several hours after a toxic ingestion and may include severe confusion, decrease in loss of reflexes, severe drowsiness, change in body temperature,

HEXOBARBITAL

Catalog Number: 1307003

Package Size: 500 mg

Revision Date:

May 26, 2004

slow or troubled breathing, slow heartbeat, slurred speech, staggering, unusual movements of the eyes, and severe weakness. Central nervous system and respiratory depression may progress to absence of reflexes, slight constriction of the pupils (in severe toxicity, pupils may be dilated), decreased urination, rapid heart beat, lowered body temperature, and coma. Typical shock syndrome, lack of breathing, circulatory collapse, and death may occur.

Acute: Possible eye, skin, gastrointestinal and/or respiratory tract irritation.

Chronic: Possible hypersensitization, liver damage (yellow eyes or skin), osteopenia or rickets (bone pain, tenderness, or aching; loss of appetite; muscle weakness; unusual weight loss), tolerance, and dependence.

Inhalation: May cause irritation. Remove to fresh air.

Eye: May cause irritation. Flush with copious quantities of water.

Skin: May cause irritation. Flush with copious quantities of water.

Ingestion: May cause irritation. Flush out mouth with water.

Medical Conditions

Aggravated by Exposure: Hypersensitivity to material, alcohol or drug use or dependence, porphyria, respiratory disease, impaired liver function, and acute or chronic pain.

Cross Sensitivity: Persons sensitive to one of the barbiturates may be sensitive to this material also.

Pregnancy Comments: Barbiturates have been shown to cause an increased incidence of fetal abnormalities, and use during the last trimester of pregnancy may cause physical dependence and withdrawal in the newborn.

Pregnancy Category: D

SECTION 4 - FIRST AID MEASURES

General: Remove from exposure. Remove contaminated clothing. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention. If person is not breathing give artificial respiration. If breathing is difficult give oxygen. Obtain medical attention.

Overdose Treatment: Treatment of barbiturate overdose should be symptomatic and supportive and may include the following:

1. Administer activated charcoal as a slurry. This is most effective when administered within one hour of ingestion.
2. Consider gastric lavage if it can be performed soon after ingestion, unless contraindicated. Control seizures prior to initiation and protect airway.
3. For hypotension: Infuse 10 to 20 mL/kg isotonic fluid. If hypotension persists, administer dopamine or norepinephrine.
4. Hemodialysis has been used successfully in short acting barbiturate intoxication. Charcoal or resin hemoperfusion is more effective and should be considered in patients with hypotension not responsive to supportive care. [Meditext 2004]

SECTION 5 - TOXICOLOGICAL INFORMATION

Oral Rat: LD50: n/f

Oral Mouse: LD50: 468 mg/kg

Irritancy Data: n/f

Target Organ(s): Central nervous system

Listed as a Carcinogen? NTP: No IARC: No OSHA: No

Other: No

SECTION 6 - FIREFIGHTING MEASURES

HEXOBARBITAL

Catalog Number: 1307003

Package Size: 500 mg

Revision Date:

May 26, 2004

Flash Point: n/f

Upper Flammable Limit: n/f

Auto-Ignition Temperature: n/f

Lower Flammable Limit: n/f

Extinguisher Media: Water spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and materials.

Fire and Explosion Hazards: This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity.

Firefighting Procedures: As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

SECTION 7 - PHYSICAL HAZARDS

Conditions to Avoid: n/f

Incompatibilities: Oxidizing agents.

Decomposition Products: When heated to decomposition material emits toxic fumes of NOx. Emits toxic fumes under fire conditions.

Stable? Yes **Hazardous Polymerization?** No

SECTION 8 - HANDLING / SPILL / DISPOSAL MEASURES

Handling: As a general rule, when handling USP Reference Standards avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling.

Storage: Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

Spill Response: Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using a high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately-labelled container for disposal. Wash spill site.

Disposal: Dispose of waste in accordance with all applicable Federal, State and local laws. Additionally, because this is a controlled substance, notify local DEA office for appropriate disposal procedures.

SECTION 9 - EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory Protection: Use a NIOSH approved respirator, if it is determined to be necessary by an industrial hygiene survey involving air monitoring. In the event that a respirator is not required, an approved dust mask should be used.

Ventilation: Recommended.

Gloves: Rubber

Eye Protection: Safety Goggles

Protective Clothing: Protect exposed skin.

SECTION 10 - PHYSICAL AND CHEMICAL PROPERTIES

NOTE: The data reported below is general information, and is not specific to the USP Reference Standard Lot provided!

Appearance and Odor: Colorless crystals or white crystalline powder; odorless.

Melting Point: 144 - 147° C

Solubility in Water: Practically insoluble

Vapor Density: n/f

Boiling Point: n/f

Evaporation Rate: n/f

HEXOBARBITAL

Catalog Number: 1307003 **Package Size:** 500 mg

Revision Date: May 26, 2004

Specific Gravity: n/f

Reactivity in Water: n/f

Vapor Pressure: n/f

% Volatile by Volume: n/f